16 September, 2025 - Distefar del Sur SL

[recaptcha]

I have read and accept the privacy policy

Check here if you consent to your data being processed in order to process your inquiry / request. If you do not authorize, your inquiry / request can not be processed.

In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

Basic information about Data Protection

Epigraph	Basic information Data Protection
Responsable	DISTEFAR DEL SUR, S.L.
Purpose	Process your inquiry / request Detailed information on Data Protection
Legitimation	Consent Detailed information on Data Protection
Recipients	It is not expected to carry out data communications to third parties, except legal obligation Transfers of data to third countries outside the European Union will not be carried out Detailed information on Data Protection
Rights	You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection
Additional Information	You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.

Farmaindustria welcomes the announcement by the Spanish Agency for Medicines and Health Products (AEMPS) to expand the accelerated assessment of early-stage clinical trials, as this strengthens the Spanish biomedical research ecosystem.

CENTRAL

DELEGACIÓN MADRID

Enlaces de interés